Biotech’s DeepSeek moment: Hong Kong investor ORI sees opportunity in China with new fund

INSUBCONTINENT EXCLUSIVE:

ORI Capital is planning a US$350 million fund to focus on Chinese biotech, with hopes that AI will help beat the market.